Analysis of regulated and practiced prices for the most consumed medicines in Brazil
Abstract
The economic regulation carried out by the Medicines Market Regulation Chamber (CMED) beginning in 2003, aims to promote pharmaceutical assistance through mechanisms that stimulate the supply of medicines and the competitiveness of the sector. Since 2007, Brazilian studies have shown that the current model of economic regulation has been unable to control the variability of drug prices sold in Brazil. The present study observes a high discrepancy between the price practiced at the points of sale and the maximum sale price to the consumer, in the years 2021 and 2022, and active monitoring of the market that was ineffective, as records of products that did not comply with the current pricing rules were found. Therefore, there is a need to make economic regulation more effective and dynamic to the reality of the market and the consumer to help Brazil guarantee the population's access to essential medicines at fair prices.
Published
Issue
Section
License
Authors who publish in this journal agree to the following terms: Authors retain copyright and grant the journal the right of first publication, with the work simultaneously licensed under a Creative Commons Attribution License, which allows the sharing of the work with acknowledgment of authorship and initial publication in this journal. Authors are authorized to enter into additional contracts separately for the non-exclusive distribution of the version of the work published in this journal (e.g., publish in an institutional repository or as a book chapter), with acknowledgment of authorship and initial publication in this journal. All content of the journal, except where identified, is licensed under a Creative Commons Attribution BY-NC License.
